EDWARDS LIFESCIENCES CORPORATION Edwards Lifesciences Corporation Stock Börse Stuttgart
Equities
EWL
US28176E1082
Advanced Medical Equipment & Technology
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 79.68 EUR | -0.18% |
|
-3.75% | +15.21% |
| May. 23 | Some of the biggest splits in Corporate America | RE |
| May. 22 | Citigroup Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $98 | MT |
| Sales 2024 * | 6.56B 6.05B | Sales 2025 * | 7.2B 6.64B | Capitalization | 52.45B 48.33B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.61B 1.49B | Net income 2025 * | 1.86B 1.72B | EV / Sales 2024 * | 7.74 x |
| Net cash position 2024 * | 1.69B 1.55B | Net cash position 2025 * | 2.87B 2.64B | EV / Sales 2025 * | 6.88 x |
| P/E ratio 2024 * |
32.9
x | P/E ratio 2025 * |
28.3
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on Edwards Lifesciences Corporation
More recommendations
More press releases
More news
| 1 week | -3.75% | ||
| Current month | +0.86% | ||
| 1 month | +0.14% | ||
| 3 months | -0.27% | ||
| 6 months | +30.85% | ||
| Current year | +15.21% |
1 week
79.52
83.91
1 month
78.1583.91
3 years
57.26118.62
5 years
47.84118.62
10 years
9.58118.62
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 14-12-31 | |
Scott Ullem
DFI | Director of Finance/CFO | 57 | 13-12-31 |
Todd Brinton
CTO | Chief Tech/Sci/R&D Officer | - | 19-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leslie Heisz
BRD | Director/Board Member | 63 | 16-07-04 |
| Chairman | 67 | 14-11-12 | |
Steven Loranger
BRD | Director/Board Member | 72 | 16-03-15 |
| Date | Price | Change |
|---|---|---|
| 24-05-29 | 79.52 | -0.38% |
| 24-05-28 | 79.82 | -1.15% |
| 24-05-27 | 80.75 | -0.23% |
| 24-05-24 | 80.94 | +0.20% |
| 24-05-23 | 80.78 | -3.73% |
Delayed Quote Börse Stuttgart, May 29, 2024 at 02:06 am EDT
More quotes
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
87.04
USD
Average target price
96.16
USD
Spread / Average Target
+10.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.87% | 219B | |
| +11.83% | 192B | |
| +18.87% | 142B | |
| +30.03% | 111B | |
| +2.28% | 65.32B | |
| +2.68% | 49.8B | |
| +6.60% | 43.43B | |
| +1.85% | 35.95B | |
| +20.43% | 30.43B |
- Stock Market
- Equities
- EW Stock
- EWL Stock
